Amyris, Inc. (NASDAQ:AMRS) Given Average Rating of “Buy” by Brokerages

Shares of Amyris, Inc. (NASDAQ:AMRS) have received a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $18.23.

Several brokerages have commented on AMRS. Roth Capital lifted their price objective on shares of Amyris from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. HSBC started coverage on shares of Amyris in a research report on Tuesday, June 1st. They issued a “buy” rating and a $20.00 price target on the stock. HC Wainwright boosted their price target on shares of Amyris from $11.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 3rd. Finally, Zacks Investment Research raised shares of Amyris from a “sell” rating to a “hold” rating in a research note on Wednesday.

Shares of AMRS traded up $0.20 during trading hours on Friday, reaching $15.83. 84,361 shares of the stock traded hands, compared to its average volume of 4,552,202. The stock has a fifty day moving average price of $14.55. Amyris has a 52 week low of $1.88 and a 52 week high of $23.42. The stock has a market cap of $4.67 billion, a P/E ratio of -6.37 and a beta of 1.10.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, May 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.92). The company had revenue of $176.90 million for the quarter, compared to the consensus estimate of $73.36 million. The business’s revenue for the quarter was up 507.9% compared to the same quarter last year. On average, equities research analysts predict that Amyris will post -1.35 earnings per share for the current fiscal year.

In other news, Director Frank Kung sold 4,678,363 shares of the business’s stock in a transaction that occurred on Tuesday, April 13th. The shares were sold at an average price of $14.96, for a total value of $69,988,310.48. Following the completion of the sale, the director now directly owns 2,266 shares in the company, valued at approximately $33,899.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 44.40% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. The PNC Financial Services Group Inc. bought a new position in Amyris in the 1st quarter worth $36,000. Parallel Advisors LLC grew its position in shares of Amyris by 1,775.0% in the 4th quarter. Parallel Advisors LLC now owns 6,000 shares of the biotechnology company’s stock worth $37,000 after buying an additional 5,680 shares during the period. Hall Laurie J Trustee grew its position in shares of Amyris by 128.7% in the 1st quarter. Hall Laurie J Trustee now owns 1,990 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,120 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Amyris in the 1st quarter worth about $57,000. Finally, IFP Advisors Inc grew its position in shares of Amyris by 280.8% in the 4th quarter. IFP Advisors Inc now owns 9,493 shares of the biotechnology company’s stock worth $60,000 after buying an additional 7,000 shares during the period. Institutional investors own 36.08% of the company’s stock.

About Amyris

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets.

Featured Story: How Buying a Call Option Works

Analyst Recommendations for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.